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1. Introduction
Hydrochlorothiazide  is  chemically  6-chloro-1,  1-
dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide is first-line diuretic drug of the thiazide 
class  that  acts  by  inhibiting  the  kidneys  ability  to 
retain water. It is calcium-sparing diuretic; frequently 
used  for  the  treatment  of  hypertension,  congestive 
heart failure, symptomatic edema, diabetes insipidus, 
renal  tubular  acidosis,  and the prevention of  kidney 
stones. It is official in Indian Pharmacopoeia, British 
Pharmacopoeia, European Pharmacopoeia and United 
States  Pharmacopeia.  Losartan  potassium  is 
chemically ([2-butyl-4-chloro-1-({4-[2-(2H-1, 2, 3, 4-
tetrazol-5-yl)  phenyl]  phenyl}  methyl)-1H-imidazol-
5-yl] methanol monopotassium. It is an angiotensin II 
receptor  antagonist  drug  used  mainly  to  treat  high 
blood pressure (hypertension). It is official in United 
States  Pharmacopeia,  British  Pharmacopoeia  and 
Japanese Pharmacopoeia. A literature survey revealed 
spectrophotometry  and  Ion  Pair  Chromatographic 
Technique1,2,3,  HPTLC4 and  RP-HPLC5-10. 
Hydrochlorothiazide  12.5mg  and  Losartan  50mg  in 
combination  is  available  in  market  by  brand  name 
Losartas-HT  which  is  an  antihypertensive 
formulation. The structure of a) Hydrochlorothiazide 
and b) Losartan Potassium is shown in Figure 1.
Figure 1: Structure of a) Hydrochlorothiazide and b) Losartan Potassium
                                                         a)                                               b)
A  literature  survey  reveals  that  there  are  few 
analytical  methods  reported  for  the  estimation  of 
Hydrochlorothiazide  alone  and  in  combination  with 
Losartan Potassium11,12 or in combination with other 
antihypertensive  drugs.  However  the  reported 
methods  have  several  limitations.  In  one  of  the 
reported method retention time for Losartan potassium 
was not found to be significant  which limits its use 
and in  another;  flow rate  for  separation  of  both the 
drugs found to be >1ml/min which means excess of 
solvent is required throughout the analysis compared 
to usual flow rates (1±0.2ml/min) which is ideal  for 
good  column  performance.  Therefore  in  order  to 
overcome  the  drawbacks  of  the  reported  methods; 
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need arised to develop a new method which should be 
suitable  for  routine  analysis  of  these  drugs  in 
combination. The present  study is able to overcome 
the drawbacks in the sense of being economical and 
with  significant  retention  time  for  both  the  drugs 
which proves that present method is perfect compared 
to reported methods.
2. Experimental
2.1 Materials: HCTZ and LOS were kindly obtained 
from Glenmark pharmaceuticals limited. Losartas-HT 
tablets 50mg were purchased from the local market. 
HPLC  grade  methanol,  acetonitrile  and  phosphate 
buffer were used. Deionized was used throughout the 
experiment. 
2.2 Instrumentation:  The separation  of  HCTZ and 
LOS was achieved  by using Younglin HPLC pump 
spectra ACME-9000 system with GRACE C18 [4.6 x 
250  mm]  10mm  column  and  UV-730D  detector 
connected to AUTO-3000 Software was used for the 
study.
2.3Optimized  Chromatographic  Conditions:  A 
GRACE C18 [4.6 x 250 mm] column was used for the 
separation of drugs.  The mobile phase comprised of 
Acetonitrile:  Buffer (50:50) pH 3.1 in proportion of 
50:50(v/v)  with  pH of  phosphate  buffer  adjusted  to 
(3.1)  using  orthophosphoric  acid.  Injection  volume 
was 20μl and run time was 15min and flow rate 1.0 
ml/min.  The  column  was  maintained  at  ambient 
temperature and the eluent was detected at  226 nm. 
The separation  of  HCTZ and LOS under  optimized 
condition is shown in Figure 2.
Figure 2: Typical HPLC chromatogram 
corresponding to mixed standard solution of 
HCTZ and LOS
2.4 Preparation of Standard solution:
HCTZ stock and working solution:  Standard stock 
solution  (100µg/ml)  of  HCTZ  was  prepared  by 
dissolving  in  methanol.  The  working  standard 
solutions were prepared to get various concentrations 
of HCTZ ranging from 2-10 µg/ml.
LOS  stock  and  working  solution:  Standard  stock 
solution  (100µg/ml)  of  LOS  was  prepared  by 
dissolving  in  methanol.  The  working  standard 
solutions were prepared to get various concentrations 
of LOS ranging from 8-40 µg/ml.
2.5 Preparation of Sample solution: Twenty tablets 
were  weighed  and  content  emptied.  The  average 
weight determined. It was finely powdered and mixed 
thoroughly.  Accurately  weighed  tablet  powder 
equivalent to 12.5 mg of HCTZ and 50 mg LOS was 
transferred in a 100 ml volumetric flask and methanol 
was  added.  It  was  shaken  vigorously  for  5  to  10 
minutes. Later the volume was made up to mark with 
methanol. The solution was filtered through whatman 
filter  paper  No.42.  Further  dilution  was  done  with 
methanol to get concentration of 12.5 mg/ml of HCTZ 
and 50 mg/ml of LOS.
2.6  System  suitability:  System  suitability  is  a 
pharmacopoeial  requirement  and  is  used  to  verify, 
whether  the  resolution  and  reproducibility  of  the 
chromatographic system are adequate for analysis to 
be done. The tests were performed by collecting data 
from 5 replicate injections of standard solutions. The 
values  obtained  demonstrated  the  suitability  of  the 
system for the analysis of this drug combination and 
the  system  suitability  parameters  fall  within  ±2% 
standard  deviation  range  during  performance  of  the 
method. Here tailing factor  for  peaks of HCTZ and 
LOS was less than 2% and resolution was satisfactory. 
The results  of  system suitability  tests  are  shown in 
Table 1.
Table 1: System suitability test results
Sr. No. Parameters HCTZ LOS
1. Peak area 483.18 1167.70
2. No. of theoretical plates 5456.06 8343.72
3. Retention time (min) 4.18 8.04
4. Asymmetry 1.47 1.29
3. Results and Discussion
The  chromatographic  conditions  were 
optimized  to  develop  RP-HPLC  method  for 
simultaneous determination of HCTZ and LOS with 
adequate resolution and rapid analysis time.
3.1  Method  Validation:  The  developed 
chromatographic method for simultaneous estimation 
of  MET  and  VILD  was  validated  according  ICH 
guidelines  for  linearity,  accuracy,  precision, 
specificity, robustness and ruggedness. 
3.1.1  Linearity:  According  to  USP;  tablet  powder 
equivalent to 60, 70, 80, 90, and 100% of label claim 
was  taken  and  dissolved  in  acetonitrile,  diluted 
appropriately  with  acetonitrile  to  obtain  a 
concentration in the range of 60%-100% of the test 
concentration. Each of this concentration was injected 
to  get  reproducible  response.  The  calibration  curve 
was  plotted  as  concentration  of  the  respective  drug 
versus  the  response  at  each  level.  The  proposed 
method  was  evaluated  by  its  correlation  coefficient 
and intercept value calculated in the statistical study. 
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The results of the linearity studies are shown 
in Table 2.
Table 2: Linearity study data
Sr. No. Drugs Slope Intercept Correlation 
Coefficient 
(R2)
1 HCTZ 19.10 8.556 0.998
2 LOS 29.58 15.36 0.998
3.1.2  Recovery:  The  accuracy  of  the  method  was 
determined  by  recovery  experiments.  The  recovery 
studies  were  carried  out  using  standard  addition 
method at 80, 100 and 120 % level; known amount of 
standards  was  added  to  reanalyzed  sample  and 
subjected  them  to  the  proposed  HPLC  method. 
Percentage recovery was calculated from the amount 
found and actual amount added. The mean recovery is 
within  acceptable  limits  which  indicate  that  the 
method is accurate .The results of recovery studies are 
shown in Table 3.
Table 3: Recovery study data
Sr. No. Drug % Recovery %RSD
1 HCTZ 99.79 0.30
2 LOS 99.89 0.06
3.1.3 Precision: The precision of an analytical method 
is  expressed  in  terms  of  SD  or  RSD  of  series  of 
measurements.  It  was  ascertained  by  replicate 
estimation of  HCTZ and LOS by proposed method. 
Percentage  relative  standard  deviation  (%RSD)  was 
found to be less than 2% which proves that method is 
precise.  The results of precision study are shown in 
Table 4.
Table 4: Precision study data
Sr.
No
Weight  of sample Peak area of std Peak area of sample % Label claim
(mg) HCTZ LOS HCZ LOS HCTZ LOS
1. 225
1905.23 2960
1905.31 2959.99 100.0 99.99
2. 225.10 1905.19 2960.17 99.98 99.94
3. 225.60 1904.34 2959.89 99.96 100.0
Mean 99.98 99.97
S.D. 0.02 0.03
%R.S.D. 0.02 0.03
3.1.4  Specificity  of  the  method:  Specificity  was 
measured as ability of the proposed method to obtain 
well separated peak for HCTZ and LOS without any 
interference  from  component  of  matrix.  The 
specificity  of  the  method  was  checked  for  the 
interference  of  impurities  in the analysis  of  a blank 
solution (without any sample) and then a drug solution 
was  injected  into  the  column,  under  optimized 
chromatographic  conditions  to  demonstrate  the 
separation of both HCTZ and LOS from any of the 
impurities, if present. As there was no interference of 
impurities and also no change in the retention time, 
the  method  was  found  to  be  specific  and  also 
confirmed  with  the  results  of  analysis  of  tablet 
formulation. The mean retention time for HCTZ and 
LOS  was  found  to  be  4.083  and  7.466  min 
respectively.
3.1.5  Robustness:  Robustness  of  the  method  was 
determined  by  making  slight  changes  in  the 
experimental conditions such as the, pH of the mobile 
phase,  and  flow  rate  of  the  mobile  phase  and  the 
chromatographic  characteristics  were  evaluated.  It 
was observed that there were no marked changes in 
the chromatograms, which demonstrated that, the RP-
HPLC method developed, are rugged and robust. The 
results of robustness study are shown in Table 5. 
Table 5: Robustness study data
System suitability
Parameters 
% RSD of peak area response 
(n=3)
Mean tailing factor
(n=3)
Mean retention time in min. 
(n=3)
Variations HCTZ LOS HCTZ LOS HCTZ LOS
Change in flow Rate +10 1.92 1.43 1.0 1.55 1.40 1.10
0 1.90 1.27 0.23 0.05 0.66 1.13
-10 1.93 1.85 0.56 0.06 1.2 1.12
Change in % Organic 
phase (Methanol)
+10 1.92 1.43 1.0 1.68 1.96 1.90
0 1.90 1.27 0.23 0.05 0.66 1.13
-10 2.0 1.75 0.56 0.08 1.2 1.18
Change in pH +0.2 1.92 1.98 1.0 0.68 1.98 1.90
0 1.90 1.27 0.23 0.05 0.66 1.13
-0.2 2.0 1.89 1.23 0.66 1.6 1.18
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3.2 Application of the method in tablets: Equal volume (20mL) of standard and sample solution was injected 
separately after equilibrium of stationary phase. The chromatograms were recorded and the response i.e. peak 
area of major peaks were measured. The procedure was repeated three times, individually weighing the tablet 
powder each time. The responses from the standard and sample were used to calculate the amounts of the drug 
in the tablet. Results obtained are shown in Table 6. The chromatogram showing separation of HCTZ and 
LOS in tablet formulation is shown in Figure 3.
Table 6: Results of Tablet formulation study
Sr.
No.
Weight of std.(mg) Weight of sample
(mg)
Peak area of std Peak area of sample % Label claim
HCTZ LOS HCTZ LOS HCTZ LOS HCTZ LOS
1.
12.5 50
225
140.41 586.52
141.38 584.93 100.69 99.72
2. 224.95 141.30 584.84 100.63 99.71
3. 225.05 141.95 585.62 101.09 99.85
Mean 100.80 99.76
S.D. 0.25 0.07
%RSD 0.24 0.078
Figure 3: Typical HPLC Chromatogram 
corresponding to marketed formulation of HCTZ 
and LOS
4. Conclusion
The  developed  RP-HPLC  method  for 
simultaneous  determination  of  HCTZ  and  LOS  in 
tablet  dosage  form  is  new,  simple,  sensitive  and 
reproducible. Therefore it can be used in routinely for 
simultaneous estimation of HCTZ and LOS in bulk as 
well as in pharmaceutical dosage form. The developed 
method was validated to find out the suitability of the 
method and it was found to be valid and suitable for 
intended purpose.
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